R
RayzeBio
Defeating cancer with radiopharmaceutical medicines
About RayzeBio
RayzeBio is a vertically integrated radiopharmaceutical therapeutics company focused on improving cancer patient survival through the development of targeted, innovative drugs that harness the power of radioisotopes. The company operates in the oncology market, serving cancer patients with solid tumors, including metastatic disease. RayzeBio's business model involves the discovery, preclinical evaluation, and clinical development of radiopharmaceutical drug candidates. The company makes money by advancing its drug candidates through clinical trials and eventually bringing them to market, where they can be used to treat cancer patients. RayzeBio has built a diverse portfolio of drug candidates ranging from early discovery to late-stage clinical programs, leveraging over 500 in vivo experiments and a systematic, data-driven approach to drug development. The company aims to selectively kill cancer cells by delivering radioisotopes intravenously in a targeted manner directly to tumors.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2023
Open roles
RayzeBio in the San Diego ecosystem
The RayzeBio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Versant Ventures
venBio Partners
Samsara BioCapital- VPVenrock Healthcare Capital Partners
Viking Global Investors
Redmile Group
Logos Capital
Venrock
OrbiMed
Alexandria Venture Investments
Cormorant Asset Management
LifeSci Venture Partners
Series B and later10 investors entered at this stage
Vivo Capital- APAcuta Capital Partners
TCGX
Perceptive Advisors
Deerfield
Wellington Management
Sofinnova Investments
Laurion Capital Management- SCSoleus Capital
Ally Bridge Group
Source: Dealroom Talent Intelligence.
Patents
14 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See RayzeBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
RYZ101 meets progression-free survival endpoint in Phase 3 ACTION-1 trial for GEP-NETs
